Resources for self-insured employers

Durable cell and gene therapies are here. Paying for Cures in the MIT NEWDIGS FoCUS Project is your source for thoughtful, thorough, and inclusive strategies to grapple with the emerging challenges of making them accessible to your team and sustainable to your company.

Featured video

Paying for Cures: Framing the solutions

Following up on Dr Jane Barlow's introduction to the issues, Mark Trusheim outlines solutions to the challenges of financing and reimbursing for cell and gene therapies.
Image
New ideas

Precision Financing Solutions

Durable therapies create three financial challenges: Payment timing, therapeutic performance risk, and actuarial risk. The NEWDIGS FoCUS consortium has worked to address the need for new, innovative financing and reimbursement models for durable/potentially curative therapies in the US to ensure patient access and sustainability for all stakeholders.

Called Precision Financing Solutions, our innovative and evolving recommendations can help self-insured employers evaluate their risks and explore combinations of solutions to meet the challenges they face.

Get the Precision Financing Solutions white paper

Image
Overview

Payer perspectives on financing and reimbursing cures

The reimbursement of emerging one-time high-cost durable/potentially curative cell and gene therapies is likely to be a challenge for US payers. The pricing of currently approved treatments and the cumulative cost impact as pipeline agents are approved are likely to challenge payers’ ability to provide affordable health coverage.

We surveyed payers to understand their interest in considering new financing approaches, the potential priority and timing of their actions, and considerations for adoption.

Get the white paper

Rows of arrows pointing left to right, with yellow arrow at front
Deep dive

Tracking the CAR-T Revolution

Chimeric antigen receptor and T-cell receptor (CAR-T/TCR) cellular immunotherapies have shown remarkable success in the treatment of some refractory B-cell malignancies, with potential to provide durable clinical response for other types of cancer.

In this paper, we look at all available FDA CAR-T/TCR clinical trials for the treatment of cancer, and analyze them with respect to different indications, targeted antigens, products, and originator locations.

Get the white paper


Send feedback

We want to know what works for you, and what doesn't. Please share your thoughts with us!

    Subscribe to news

    Join our mailing list to keep up to date on Paying for Cures news and events. 


    Image

    Paying for Cures is an initiative of the FoCUS Project at MIT

    FoCUS seeks to collaboratively address the need for new, innovative financing and reimbursement models for durable therapies that ensure patient access and sustainability for all stakeholders. This multi-stakeholder effort unites developers, providers, regulators, patient advocacy groups, payers from all segments of the US healthcare system, and academics working in healthcare policy, financing, and reimbursement.

    FoCUS research and design

    • Engaged cross-sector, multi-stakeholder group to identify challenges and cooperatively design sustainable solutions
    • Analyzed drug pipeline to understand scale of the challenge
    • Described system of “Cure Archetypes” and how different kinds of healthcare payers can support them
    • Designed and served as a catalyst for Precision Financing pilots to test real-world application

    MIT Center for Biomedical Innovation
    NEWDIGS Initiative
    Massachusetts Institute of Technology
    E19–604
    77 Massachusetts Avenue
    Cambridge, MA 02139

    newdigs@mit.edu
    Phone: 617-324-9640
    Fax: 617-253-0687

    Image Image